Delayed contrast-enhanced MRI to localize Botox after cystoscopic intravesical injection
Conclusions Diffusion of BoNT after intravesical injection is very common once bladder wall is breeched. Precise injection localization into muscle layer may not be as relevant to outcome as previously assumed. The assumption in our study that localization and diffusion of contrast also represents the localization of BoNT is open to critique as BoNT diffusion is potentially slower (Mehnert et al. in World J Urol 27(3):397–403, 2009). The absence of systemic symptoms after the injection in our series supports guidelines concerning the safety of procedure. (Source: International Urology and Nephrology)
Source: International Urology and Nephrology - April 19, 2015 Category: Urology & Nephrology Source Type: research

Myoxinol (Hydrolyzed Hibiscus esculentus Extract) in the Cure of Chronic Anal Fissure: Early Clinical and Functional Outcomes.
Conclusions. The topical application of Myoxinol 3% ointment in the cure of CAF shows encouraging early results. Further researches with a larger series and a longer follow-up are needed to confirm these data. PMID: 25861259 [PubMed] (Source: Gastroenterology Research and Practice)
Source: Gastroenterology Research and Practice - April 12, 2015 Category: Gastroenterology Tags: Gastroenterol Res Pract Source Type: research

Cortical activation changes and improved motor function in stroke patients after focal spasticity therapy– an interventional study applying repeated fMRI
Conclusions: Comprehensive focal spasticity management was also in this study associated with brain reorganization in a “normalizing” left/right lateralization direction in addition to improved motor function. Furthermore, quantification of BOLD intensity in specified BAs showed reduced neuronal “over-activity” in the injured brain after therapy. (Source: BMC Neurology)
Source: BMC Neurology - April 11, 2015 Category: Neurology Authors: Ulla BergfeldtTomas JonssonLennart BergfeldtPer Julin Source Type: research

Botox (onabotulinumtoxinA) for treatment of post traumatic chronic migraine headaches (PTCMH) in veterans (P1.318)
CONCLUSION: In conclusion, with proper administration of Botox, veterans who suffer from TBI and have failed conventional treatment showed significant improvement in ADL, migraine severity, frequency, and duration of PTCMH.Disclosure: Dr. Roka has nothing to disclose. Dr. zachariah has nothing to disclose. Dr. Badiali has nothing to disclose. Dr. Zachariah has nothing to disclose. (Source: Neurology)
Source: Neurology - April 8, 2015 Category: Neurology Authors: Roka, A., Zachariah, A., Badiali, E., Zachariah, S. Tags: Headache I Source Type: research

Post-denervation muscle hypertrophy: a rare complication of brachial plexopathy. (P3.177)
CONCLUSIONS: Muscle hypertrophy is a rare and potentially disabling condition that can follow brachial plexopathy and is associated with an underlying focal myositis . Repetitive electrical discharges of myofibers recovering from denervation may lead to myofiber hypertrophy. The etiology of focal myositis is not well understood. It may represent an inflammatory response associated with local tissue injury.Disclosure: Dr. Vivar Cruz has nothing to disclose. Dr. Rezania has received personal compensation for activities with Walgreens and Genzyme Corporation. Dr. Pytel has nothing to disclose. Dr. Haydon has nothing to disclo...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Vivar Cruz, P., Rezania, K., Pytel, P., Haydon, R., Roos, R. Tags: Neuromuscular Disease: Clinical Neurophysiology Source Type: research

SUNCT responding to botulinum toxin (P3.049)
Conclusions: OnabotulinumtoxinA injection is a therapeutic option for refractory cases of SUNCT.Disclosure: Dr. Wijemanne has nothing to disclose. Dr. Jankovic has received personal compensation for activities with Adamas Pharmaecuticals, Inc, Allergan, Inc, Auspex Pharmaceuticals, Inc, Lundbeck Inc, and Teva Pharmaceutical Industries Ltd. Dr. Jankovic has received personal compensation in an editor (Source: Neurology)
Source: Neurology - April 8, 2015 Category: Neurology Authors: Wijemanne, S., Jankovic, J. Tags: Headache II Source Type: research

A Structured Interview Evaluating Botulinum Toxin Type A Treatments for blepharospasm (P4.328)
CONCLUSIONS: Patients showed most satisfaction at maximum effect and preferred injection intervals less than the standard 12 weeks. JRS and BSDI results indicated patients continued to have symptoms. Studies are warranted to confirm the time course of patient satisfaction and determine optimal dosing interval. Study Supported by: Merz North America, Inc.Disclosure: Dr. Sethi has received personal compensation for activities with Synosia, Lundbeck Research USA, Inc., Auspex Pharmaceuticals, Veloxis Pharmaceuticals, Adamas Pharmaceuticals, Impax Laboratories, Teva Neuroscience, and US WorldMeds as a consultant and/or Dr. Fez...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Sethi, K., Fezza, J., Burns, J., Woodward, J., Truong, D., Hedges, T., Taupin, P., Verma, A. Tags: Movement Disorders: Dystonia Source Type: research

Botulinum Toxin for the Treatment of Extra-Pyramidal Symptoms of Lesch-Nyhan Syndrome (P6.252)
CONCLUSIONS:We hypothesize that botulinum toxin type A, both incobotulinum (Xeomin) and onabotulinum (Botox) may be an effective treatment of dystonia and opisthotonus in patients with LNS and may also improve self injurious behavior. Further prospective studies are needed.Disclosure: Dr. Zecavati has nothing to disclose. Dr. Santos has nothing to disclose. Dr. Oyegbile has nothing to disclose. (Source: Neurology)
Source: Neurology - April 8, 2015 Category: Neurology Authors: Zecavati, N., Santos, C., Oyegbile, T. Tags: Child Neurology and Developmental Neurology: Other Source Type: research

Biopsy and EMG Findings in a Case of Late-Onset Dropped Head Syndrome After Mantle Field Radiotherapy (P7.098)
CONCLUSIONS: This study supports the increasingly common mixed neuromyopathic picture of late onset radiation induced dropped head syndrome in patients with Hodgkin's Lymphoma who received mantle radiation therapy. This study provides electrodiagnostic and biopsy based support for the mixed neuromyopathic picture. This diagnosis should be entertained to avoid the pitfalls of Botox therapy. Study Supported by: NOT APPLICABLEDisclosure: Dr. Stino has nothing to disclose. Dr. Ross has received personal compensation for activities with Baxter. (Source: Neurology)
Source: Neurology - April 8, 2015 Category: Neurology Authors: Stino, A., Ross, M. Tags: Neuropathy: Clinical Trials, Diagnostic Testing, and Treatment Source Type: research

Botulinum Toxin Type A and Rat Trigeminal Regions: The Search for Mechanism of Antinociceptive Action in Migraine and Other Headaches (S51.002)
CONCLUSIONS:Antinociceptive activity of BoNT/A in trigeminal region might be associated with prevention of CGRP release from dural nerve endings but involves endogenous opioid system as well. Study Supported by: Croatian Ministry of Science, Education and SportDisclosure: Dr. Lackovic has nothing to disclose. (Source: Neurology)
Source: Neurology - April 8, 2015 Category: Neurology Authors: Lackovic, Z. Tags: Headache: Imaging and Physiology Source Type: research

Botulinum toxin in masticatory muscles of the adult rat induces bone loss at the condyle and alveolar regions of the mandible associated with a bone proliferation at a muscle enthesis
In man, botulinum toxin type A (BTX) is injected in masticatory muscles for several indications such as trismus, bruxism, or masseter hypertrophy. Bone changes in the mandible following BTX injections in adult animal have therefore became a subject of interest. The aim of this study was to analyze condylar and alveolar bone changes following BTX unilateral injections in masseter and temporal muscles in adult rats. Mature male rats (n=15) were randomized into 2 groups: control (CTRL; n=6) and BTX group (n=9). (Source: Bone)
Source: Bone - April 6, 2015 Category: Orthopaedics Authors: Jean-Daniel Kün-Darbois, Hélène Libouban, Daniel Chappard Source Type: research

Factors that influence the urodynamic results of botulinum toxin in the treatment of neurogenic hyperactivity
Conclusions The urodynamic effect of BTX-A is maintained for a considerable time interval. The IUC negatively influences the result of the treatment. (Source: Actas Urologicas Espanolas)
Source: Actas Urologicas Espanolas - April 3, 2015 Category: Urology & Nephrology Source Type: research

Effect of a Second Injection of Botulinum Toxin on Lower Facial Contouring, as Evaluated Using 3-Dimensional Laser Scanning
CONCLUSION: The administration of a second BoNT-A injection is effective for better aesthetic results for the lower facial contour. (Source: Dermatologic Surgery)
Source: Dermatologic Surgery - April 1, 2015 Category: Dermatology Tags: Original Article Source Type: research

Pd45-09 scrotox: salvage peri-spermatic cord botulinum-a toxin injections for patients with refractory chronic scrotal content pain after microsurgical denervation of the spermatic cord.
Botulinum-A toxin (Botox) has been shown to modulate the release of neuropeptides leading to inhibition of neurogenic inflammation and chronic pain. This provides an antinociceptive effect. Chronic scrotal content pain is a difficult condition to treat. Microsurgical denervation of the spermatic cord (MDSC) is one surgical treatment option with success rates published in the 60-85% range. However, patients who fail MDSC have limited options. Our goal was to assess the use of peri-spermatic cord Botox injections (Scrotox) to provide prolonged pain relief in men with refractory chronic scrotal content pain after MDSC. (Sourc...
Source: The Journal of Urology - April 1, 2015 Category: Urology & Nephrology Authors: Bayo Tojuola, Ibrahim Kartal, Jamin Brahmbhatt, Sijo Parekattil Tags: Sexual Function/Dysfunction/Andrology: Medical and Non-Surgical Therapy II Source Type: research

Pd1-06 effect of onabotulinumtoxina treatment for neurogenic detrusor over activity on the prevention of autonomic dysreflexia following spinal cord injury
Neurogenic detrusor overactivity (NDO) is a leading cause of autonomic dysreflexia (AD) in spinal cord injury (SCI). Subjective improvements in AD has been observed following OnabotulinumtoxinA (Botox©) treatment for NDO but no studies have quantitatively assessed the capacity of Botox to reduce AD frequency and severity using the clinical cut-off of an increase in systolic blood pressure (SBP) of ≥20 mmHg. (Source: The Journal of Urology)
Source: The Journal of Urology - April 1, 2015 Category: Urology & Nephrology Authors: Renee Fougere, Katharine Currie, Lynn Stothers, Mark Nigro, Daniel Rapaport, Andrei Krassioukov Tags: Urodynamics/Incontinence/Female Urology: Neurogenic Voiding Dysfunction I Source Type: research

Clinical and image improvement of Raynaud's phenomenon after botulinum toxin type A treatment
We report two patients with severe or mild Raynaud's phenomenon who were injected with BTX‐A; both of whom experienced clinical and image improvement after treatment. (Source: Australasian Journal of Dermatology)
Source: Australasian Journal of Dermatology - March 29, 2015 Category: Dermatology Authors: HongMei Zhao, YaJun Lian Tags: Case Report Source Type: research

Clinical and image improvement of Raynaud's phenomenon after botulinum toxin type A treatment.
We report two patients with severe or mild Raynaud's phenomenon who were injected with BTX-A; both of whom experienced clinical and image improvement after treatment. PMID: 25817568 [PubMed - as supplied by publisher] (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - March 29, 2015 Category: Dermatology Authors: Zhao H, Lian Y Tags: Australas J Dermatol Source Type: research

Abstract 23: Botulinum Toxin Type A as an Alternative to Surgery for the Treatment of Persistent Congenital Muscular Torticollis
No abstract available (Source: Plastic and Reconstructive Surgery)
Source: Plastic and Reconstructive Surgery - March 28, 2015 Category: Cosmetic Surgery Tags: AAPS Abstract Supplement: Abstracts & Posters Source Type: research

Abstract 5: A Quantitative Analysis of Botulinum Toxin Type A (BoNTA) Formulations: A Randomized Double Blind Prospective Clinical Trial of Comparative Dynamic Strain Reduction
No abstract available (Source: Plastic and Reconstructive Surgery)
Source: Plastic and Reconstructive Surgery - March 28, 2015 Category: Cosmetic Surgery Tags: AAPS Abstract Supplement: Abstracts & Posters Source Type: research

Cricothyroid Muscle Botulinum Toxin Injection to Improve Airway for Bilateral Recurrent Laryngeal Nerve Paralysis, A Case Series
Bilateral vocal fold paralysis most commonly results from iatrogenic trauma to the recurrent laryngeal nerve during surgical procedures in the anterior neck. Patients may require tracheostomy because of acute or gradual onset of dyspnea and airway compromise. The intralaryngeal injection of Botox has been considered as a possible therapy for these airway symptoms of bilateral vocal fold paralysis. Chronic unopposed activity of intact cricothyroid muscles could potentially result in gradual medialization of the vocal folds in patients with bilateral recurrent laryngeal nerve paralysis. (Source: Journal of Voice)
Source: Journal of Voice - March 24, 2015 Category: ENT & OMF Authors: Michael S. Benninger, Andrea Hanick, Douglas M. Hicks Source Type: research

Commentary to “Effect of Botox injection at the bladder neck in boys with bladder dysfunction after valve ablation”
The article by Mokhless et al. [1], while offering an earnest effort, far from settles the debate regarding whether or not bladder neck hypertrophy in boys with a history of posterior urethral valves (PUVs) is an obstructive condition harming bladder function and preventing resolution of already existing bladder dysfunction. We are told that all 20 boys in the study had bladder neck hypertrophy as determined by cystoscopy and none had any residual valve or stricture; however, the authors avoided using the term secondary bladder neck obstruction (BNO) maybe because they wanted to avoid any suggestion that these bladder neck...
Source: Journal of Pediatric Urology - March 14, 2015 Category: Urology & Nephrology Authors: Abdol-Mohammad Kajbafzadeh, Sorena Keihani, Kenneth I. Glassberg Tags: Letter to the Editor Source Type: research

[Treatment of spasticity in nursing homes: botulinum toxin type A as part of therapy].
We present two nursing home patients, a 95-year-old woman and a 63-year-old man, with severe upper limb complications following spasticity. Both patients received botulinum toxin injections in the affected muscles, combined with an appropriate splint. A treatment team consisting of a specialist in geriatric medicine, a rehabilitation physician, a physical and an occupational therapist provided consistent daily care in the institution. These efforts substantially reduced care-related pain and improved social behaviour and care options. If spasticity prohibits treatment or care, consultation of a rehabilitation physician at ...
Source: Pain Physician - March 7, 2015 Category: Anesthesiology Authors: Wolswijk AH, Dirkx AE Tags: Ned Tijdschr Geneeskd Source Type: research

OnabotulinumtoxinA as Part of a Multimodal Program to Treat Vaginismus
This pilot study evaluated the efficacy and safety of intravaginal injection of onabotulinumtoxinA (Botox) with bupivacaine and progressive dilation under anesthesia along with post‐treatment counseling and support in the treatment of vaginismus. At baseline, all patients had failed some form of prior treatment. Following treatment, 90.3% of patients achieved pain‐free intercourse at a median of 3.5 weeks. This multimodal program, which treats both the physical and psychologic manifestations of vaginismus, appears to be safe and effective with no adverse events and no recurrence in this cohort during at least 1‐year ...
Source: Journal of Applied Biobehavioral Research - March 5, 2015 Category: Psychiatry & Psychology Authors: Peter T. Pacik Tags: Original Article Source Type: research

Postparalysis Facial Synkinesis: Clinical Classification and Surgical Strategies
Source: Plastic and Reconstructive Surgery Global Open - March 1, 2015 Category: Cosmetic Surgery Tags: Original Articles Source Type: research

Intralesional botulinum toxin type A equally effective and better tolerated than intralesional steroid in the treatment of keloids: a randomized controlled trial
Summary Intralesional (IL) corticosteroid therapy is a treatment for keloids. IL botulinum toxin type A (BTA) has been postulated in such an indication with controversial reports. To compare efficacy and safety of IL BTA to the IL corticosteroid therapy in treatment of keloids. Twenty‐four patients with keloids were randomly divided into two equal groups: receiving IL steroid repeated every 4 weeks for six sessions (group A) and IL BTA 5 IU/cm3 repeated every 8 weeks for three sessions (group B). Objective parameters (hardness, elevation, and redness), subjective complaints (itching, pain, and tenderness), pati...
Source: Journal of Cosmetic Dermatology - March 1, 2015 Category: Dermatology Authors: Eman Shaarawy, Rehab A. Hegazy, Rania M. Abdel Hay Tags: Master Case Presentation Source Type: research

Seven reasons you are losing patients to the competition.
This article offers seven reasons practices lose patients to the competition, and what to do to course-correct. PMID: 26062331 [PubMed - in process] (Source: The Journal of Medical Practice Management : MPM)
Source: The Journal of Medical Practice Management : MPM - March 1, 2015 Category: Practice Management Authors: Chism M Tags: J Med Pract Manage Source Type: research

The Efficacy and Safety of Liquid-Type Botulinum Toxin Type A for the Management of Moderate to Severe Glabellar Frown Lines
Conclusions: The efficacy and safety of MT10109L were comparable to those of Botox for the management of glabellar frown lines. MT10109L provides greater convenience because it does not require dilution and has long-lasting effects. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II. (Source: Plastic and Reconstructive Surgery)
Source: Plastic and Reconstructive Surgery - February 28, 2015 Category: Cosmetic Surgery Tags: Cosmetic: Original Articles Source Type: research

Patient Experience with Botulinium Toxin Type A for Refractory Myofascial Pelvic Pain
To evaluate patient experience, outcomes and post-injection complications with intralevator botulinum toxin type A (Botox) for treatment of refractory myofascial pelvic pain. (Source: The Journal of Minimally Invasive Gynecology)
Source: The Journal of Minimally Invasive Gynecology - February 27, 2015 Category: OBGYN Authors: K.L. Armstrong, E. Von Bargen, M. Haviland, M.R. Hacker, E.A. Elkadry Tags: Non-Oral Poster 82 Source Type: research

Frey's syndrome and botulinum toxin type A: duration of efficacy and patient satisfaction
(Source: Journal of the European Academy of Dermatology and Venereology)
Source: Journal of the European Academy of Dermatology and Venereology - February 26, 2015 Category: Dermatology Authors: P. Dessart, E. Truchot, H. Maillard Tags: Letter to the Editor Source Type: research

Atypical Posttraumatic Dystonia Treated Successfully by Botulinum Toxin Injection
This study presents the case of a 39-yr-old woman who had atypical involuntary dystonic movements of the shoulder and back. Ten months earlier, she was involved in a motor vehicle collision. Involuntary movements developed abruptly 3 wks before her first visit to the clinic. Her involuntary movements had some atypical features, such as continuous, bizarre, and rhythmic or semirhythmic characteristics, and showed mixed symmetric and asymmetric patterns. She was treated successfully with electromyography-guided botulinum toxin type A injection. Involuntary dystonic movements may be due to posttraumatic dystonia, a relatively...
Source: American Journal of Physical Medicine and Rehabilitation - February 24, 2015 Category: Rehabilitation Tags: Case Reports Source Type: research

Dynamic Decomposition of Motion in Essential and Parkinsonian Tremor.
This study examines complexity of wrist tremor in terms of involvement of its three anatomical degrees of freedom (DOF) in two common situations of rest and posture. The study examines tremor in 11 ET and 17 PD participants by kinematic decomposition of motion in 3-DOF. Results: Tremor decomposition showed the motion involved more than one DOF (
Source: The Canadian Journal of Neurological Sciences - February 23, 2015 Category: Neurology Authors: Rahimi F, Debicki D, Roberts-South A, Bee C, Bapat P, Jog M Tags: Can J Neurol Sci Source Type: research

Re: Intrathecal Administration of Botulinum Toxin Type A Improves Urinary Bladder Function and Reduces Pain in Rats with Cystitis
Publication date: April 2015 Source:European Urology, Volume 67, Issue 4 Author(s): Apostolos Apostolidis (Source: European Urology)
Source: European Urology - February 18, 2015 Category: Urology & Nephrology Source Type: research

A systematic review of the pharmacological approaches against snoring: can we count on the chickens that have hatched?
Discussion Even though there are no consistent data to support pharmacologic treatment for primary snoring, through the critical analysis of these studies, we have discussed about the future directions for clinical trials in this area to arrive at a clinically meaningful decision. (Source: Sleep and Breathing)
Source: Sleep and Breathing - February 14, 2015 Category: Respiratory Medicine Source Type: research

A systematic review of the pharmacological approaches against snoring: can we count on the chickens that have hatched?
DISCUSSION: Even though there are no consistent data to support pharmacologic treatment for primary snoring, through the critical analysis of these studies, we have discussed about the future directions for clinical trials in this area to arrive at a clinically meaningful decision. PMID: 25680547 [PubMed - as supplied by publisher] (Source: Sleep and Breathing)
Source: Sleep and Breathing - February 14, 2015 Category: Sleep Medicine Authors: Achuthan S, Medhi B Tags: Sleep Breath Source Type: research

Effectiveness of Botulinum Toxin (Type-A) Administered by the Fixed-Site Dosing Approach Versus the Muscle Area Identification
Conclusions Botulinum toxin application is more effective when administered through the objective-muscle-identification approach (less frowning, lower doses, less fixed sites injected, and patients more satisfied at the end). Level of Evidence III This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266. (Source: Aesthetic Plastic Surgery)
Source: Aesthetic Plastic Surgery - February 12, 2015 Category: Cosmetic Surgery Source Type: research

Multiple Good Options are Available for Achalasia Management
Conclusions: MT options are available for management of achalasia. Improvement of clinical symptoms and overall patient satisfaction does not differ if the patient underwent an ST modality or a combination of different treatments. (Source: Journal of Clinical Gastroenterology)
Source: Journal of Clinical Gastroenterology - February 6, 2015 Category: Gastroenterology Tags: ALIMENTARY TRACT: Original Articles Source Type: research

The Potential and Perspective of Peroral Endoscopic Esophageal Myotomy for Achalasia
Abstract The therapeutic spectrum of this disorder consists of medical therapy, endoscopic balloon dilatation, endoscopic Botox injection, open or laparoscopic cardia myotomy, and most recently transesophageal endoscopic myotomy (POEM peroral endoscopic myotomy). The most important requirement is a well-experienced team in interventional flexible endoscopy. The endoscopist as well as the assisting staff should have experience in advanced therapeutic endoscopic techniques and hemostasis to handle all necessary endoscopic instruments such as injection needles, needle knife, triangle knife, coagulation graspers, and ...
Source: World Journal of Surgery - February 5, 2015 Category: Surgery Source Type: research

Employment of Higher Doses of Botulinum Toxin Type A to Reduce Spasticity After Stroke
Spasticity is a common disabling symptom for several neurological conditions. Botulinum toxin type A injection represents the gold standard treatment for focal spasticity with efficacy, reversibility, and low prevalence of complications. Current guidelines suggest a dose up to 600 units (U) of onabotulinumtoxinA/incobotulinumtoxinA or up to 1500 U of abobotulinumtoxinA to treat post-stroke spasticity to avoid important adverse effects. However, recently, higher doses of botulinum toxin type A were employed, especially in case of upper and lower limb severe spasticity. (Source: Journal of the Neurological Sciences)
Source: Journal of the Neurological Sciences - February 5, 2015 Category: Neurology Authors: Andrea Santamato, Maria Francesca Micello, Maurizio Ranieri, Giovanni Valeno, Antonio Albano, Alessio Baricich, Carlo Cisari, Domenico Intiso, Alberto Pilotto, Giancarlo Logroscino, Francesco Panza Source Type: research

Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia.
CONCLUSION: A cost-utility analysis found that Xeomin was the more cost-effective botulinum toxin type A product compared with Botox and Dysport for the treatment of CD. Wastage associated with the respective products may have a large effect on the cost-effectiveness of the agents. PMID: 25631837 [PubMed - in process] (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - February 2, 2015 Category: Drugs & Pharmacology Authors: Kazerooni R, Broadhead C Tags: Am J Health Syst Pharm Source Type: research

Botulinum toxin is detrimental to repair of a chronic rotator cuff tear in a rabbit model
This study provides additional support for the rabbit supraspinatus model of chronic cuff tear, showing consistent fatty infiltration. Contrary to our hypothesis, Botox had a negative effect on repair strength and might increase fatty infiltration. This article is protected by copyright. All rights reserved (Source: Journal of Orthopaedic Research)
Source: Journal of Orthopaedic Research - January 28, 2015 Category: Orthopaedics Authors: Mohit Gilotra, Thao Nguyen, Matthew Christian, Derik Davis, R. Frank Henn, Syed Ashfaq Hasan Tags: Research Article Source Type: research

Muscle weakness in treatment of palmar hyperhidrosis with botulinum toxin type a: can it be prevented?
CONCLUSIONS: BTX-A led to the reduction of disease severity while transient side effects were reported. PMID: 25607695 [PubMed - in process] (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - January 24, 2015 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Predicting the Response to Botulinum Toxin Treatment in Children With Cerebral Palsy
It is interesting to read the article by Bar-On et al.1 They compared the responsiveness of clinical and instrumented spasticity assessment for the effects of botulinum toxin type A injection in children with cerebral palsy. However, in the entire article, they used the abbreviated term BTX rather than the distinct trade name for botulinum toxin to denote the medication they injected. I strongly recommend that the authors need to clarify the formulation of botulinum toxin to avoid misunderstanding. (Source: Archives of Physical Medicine and Rehabilitation)
Source: Archives of Physical Medicine and Rehabilitation - January 20, 2015 Category: Rehabilitation Authors: Yu-Ching Lin Tags: Letter to the editor Source Type: research

Use of Botulinum Toxin Type A in the Management of Neonatal Brachial Plexus Palsy
Conclusions BoNT-A is an effective adjunct to therapy and surgery in managing muscle imbalance, cocontractions, and contractures in neonatal brachial plexus palsy. Use of BoNT-A can result in averting, modifying, or deferring surgical interventions in a number of affected children. (Source: PMandR)
Source: PMandR - January 15, 2015 Category: Rehabilitation Source Type: research

Constraint-Induced Movement Therapy After Injection of Botulinum Toxin Type A for a Patient With Chronic Stroke: One-Year Follow-up Case Report.
DISCUSSION: The improved arm function could reflect improvements in volitional movements and coordination or speed of movements in the paretic arm that resulted from a reduction in spasticity, a reduction of learned nonuse behaviors, or use-dependent plasticity after the combination of BTX type A and constraint-induced movement therapy. If this approach proves useful in future controlled studies, this may halt the rising medical costs of the treatment of stroke. PMID: 25592185 [PubMed - as supplied by publisher] (Source: Physical Therapy)
Source: Physical Therapy - January 15, 2015 Category: Physiotherapy Authors: Amano S, Takebayashi T, Hanada K, Umeji A, Marumoto K, Furukawa K, Domen K Tags: Phys Ther Source Type: research

Factors that influence the urodynamic results of botulinum toxin in the treatment of neurogenic hyperactivity.
ute;guez A, Esteban-Fuertes M Abstract OBJECTIVES: To determine the urodynamic efficacy and factors that influence the urodynamic results of treatment of neurogenic detrusor hyperactivity with intradetrusor injection of botulinum toxin type A (BTX-A) in patients with spinal cord injury (SCI). MATERIAL AND METHODS: A retrospective study was conducted with a cohort of 70 patients composed of 40 men and 30 women with stable SCI (mean age, 39±13.3 years) who underwent an intradetrusor injection of 300 IUs of BTX-A. A urodynamic study was conducted prior to the injection and 6±4.3 months after the tr...
Source: Actas Urologicas Espanolas - January 9, 2015 Category: Urology & Nephrology Authors: Gutiérrez-Martín P, Vírseda-Chamorro M, Salinas Casado J, Gómez-Rodríguez A, Esteban-Fuertes M Tags: Actas Urol Esp Source Type: research

Benign familial pemphigus ( Hailey-Hailey disease). White, Forrest; Shvartsbeyn, Marianna; Meehan, Shane A; Urbanek, Richard W
A 56-year-old man presented with a 15-year history of scaly red plaques on the trunk and axillae. Skin biopsy was consistent with Hailey-Hailey disease. His condition was refractory to multiple therapies, which included topical and oral antibiotics and topical, intralesional, and oral glucocorticoids. Treatment with subcutaneous botulinum toxin type A at the axillae and on the back led to a nearly complete resolution of plaques in those areas. Botulinum toxin type A should be considered in patients with extensive Hailey-Hailey disease who are fail traditional therapies. (Source: Dermatology Online Journal)
Source: Dermatology Online Journal - January 1, 2015 Category: Dermatology Source Type: research

Growth effects of botulinum toxin type A injected unilaterally into the masseter muscle of developing rats.
CONCLUSIONS: Localized BTX-A injection induced a change in craniofacial growth, and the skeletal effect was unilateral despite both sides of the mandible functioning as one unit. PMID: 25559955 [PubMed - in process] (Source: J Zhejiang Univ Sci ...)
Source: J Zhejiang Univ Sci ... - January 1, 2015 Category: Science Authors: Park C, Park K, Kim J Tags: J Zhejiang Univ Sci B Source Type: research

[Axillary hyperhidrosis, botulinium A toxin treatment: Review.]
Abstract Injection of type A botulinum toxin in the armpits is a temporary treatment for axillary hyperhidrosis. This technique described in 1996 by Bushara et al., is known to be efficient and safe. The purpose of this article was to review the data concerning the treatment of axillary hyperhidrosis with botulinum toxin type A, and discuss the other treatment modalities for this socially disabling entity. PMID: 25555435 [PubMed - as supplied by publisher] (Source: Annales de Chirurgie Plastique et Esthetique)
Source: Annales de Chirurgie Plastique et Esthetique - December 30, 2014 Category: Cosmetic Surgery Authors: Clerico C, Fernandez J, Camuzard O, Chignon-Sicard B, Ihrai T Tags: Ann Chir Plast Esthet Source Type: research

Quality of Life and Social Isolation in Greek Adolescents with Primary Focal Hyperhidrosis Treated with Botulinum Toxin Type A: A Case Series
The objective of the current study was to evaluate the effectiveness of botulinum toxin type A (BTXA) in adolescents with primary palmar and axillary hyperhidrosis and to determine its effect on quality of life and social isolation. Thirty‐five individuals (17 girls, 18 boys) with moderate to severe palmar and axillary hyperhidrosis were treated with BTXA (onabotulinum). Patients were examined at baseline and 6 months after treatment. The Hyperhidrosis Disease Severity Scale (HDSS) was used to evaluate disease severity and the Children's Dermatology Life Quality Index (CDLQI) was used to assess quality of life. The ...
Source: Pediatric Dermatology - December 29, 2014 Category: Dermatology Authors: Anargyros Kouris, Kalliopi Armyra, Christina Stefanaki, Christos Christodoulou, Polixeni Karimali, George Kontochristopoulos Tags: Original Article Source Type: research

Growth hormone mitigates loss of periosteal bone formation and muscle mass in disuse osteopenic rats.
Authors: Grubbe MC, Thomsen JS, Nyengaard JR, Duruox M, Brüel A Abstract Growth hormone (GH) is a potent anabolic agent capable of increasing both bone and muscle mass. The aim was to investigate whether GH could counteract disuse-induced loss of bone and muscle mass in a rat model. Paralysis was induced by injecting 4 IU Botox (BTX) into the muscles of the right hind limb. Sixty female Wistar rats, 14 weeks old, were divided into the following groups: baseline, controls, BTX, BTX+GH, and GH. GH was given at a dosage of 5 mg/kg/d for 4 weeks. Compared with controls, BTX resulted in lower periosteal bone format...
Source: Journal of Musculoskeletal Neuronal Interactions - December 23, 2014 Category: Neurology Tags: J Musculoskelet Neuronal Interact Source Type: research